



Aalborg Universitet

AALBORG UNIVERSITY  
DENMARK

## Pain in Parkinson disease

*mechanistic substrates, main classification systems, and how to make sense out of them*

de Andrade, Daniel Ciampi; Mylius, Veit; Perez Lloret, Santiago; Cury, Rubens Gisbert; Bannister, Kirsty; Moisset, Xavier; Kubota, Gabriel Taricani; Finnerup, Nanna B; Bouhassira, Didier; Chaudhuri, Kallol Ray; Graven-Nielsen, Thomas; Treede, Rolf-Detlef

Published in:  
Pain

DOI (link to publication from Publisher):  
[10.1097/j.pain.0000000000002968](https://doi.org/10.1097/j.pain.0000000000002968)

Publication date:  
2023

Document Version  
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):

de Andrade, D. C., Mylius, V., Perez Lloret, S., Cury, R. G., Bannister, K., Moisset, X., Kubota, G. T., Finnerup, N. B., Bouhassira, D., Chaudhuri, K. R., Graven-Nielsen, T., & Treede, R.-D. (2023). Pain in Parkinson disease: mechanistic substrates, main classification systems, and how to make sense out of them. *Pain*, 164(11), 2425-2434. <https://doi.org/10.1097/j.pain.0000000000002968>

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

### Take down policy

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.



# **PAIN IN PARKINSON'S DISEASE: MECHANISTIC SUBSTRATES, MAIN CLASSIFICATION SYSTEMS, AND HOW TO MAKE SENSE OUT OF THEM.**

Daniel Ciampi de Andrade\*\* <sup>a</sup>, Veit Mylius\*\* <sup>b,c</sup>, Santiago Perez-Lloret <sup>d,e</sup>, Rubens G. Cury <sup>f</sup>, Kirsty Bannister<sup>g</sup>, Xavier Moisset <sup>h</sup>, Gabriel Taricani Kubota <sup>b,i</sup>, Nanna B. Finnerup<sup>j</sup>, Didier Bouhassira <sup>k</sup>, Kallol Ray Chaudhuri <sup>l,m</sup>, Thomas Graven-Nielsen <sup>a</sup>, Rolf-Detlef Treede <sup>n</sup>.

## **Affiliations:**

<sup>a</sup> Center for Neuroplasticity and Pain (CNAP), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.

<sup>b</sup> Department of Neurology, Centre for Neurorehabilitation, Valens, Switzerland.

<sup>c</sup> Department of Neurology, Philipps University, Marburg, Germany; Department of Neurology, Kantonsspital, St. Gallen, Switzerland.

<sup>d</sup> Observatorio de Salud Pública, Universidad Católica Argentina, Consejo de Investigaciones Científicas y Técnicas (UCA-CONICET), Buenos Aires, Argentina

<sup>e</sup> Facultad de Medicina, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina; Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.

<sup>f</sup> Movement Disorders Center, Department of Neurology, University of Sao Paulo, Sao Paulo, Brazil

<sup>g</sup> Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

<sup>h</sup> Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand, France.

<sup>i</sup> Pain Center, University of Sao Paulo Clinics Hospital, Sao Paulo, Brazil. Center for Pain Treatment, Institute of Cancer of the State of Sao Paulo, University of Sao Paulo Clinics Hospital, Sao Paulo, Brazil.

<sup>j</sup> Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Denmark; Department of Neurology, Aarhus University Hospital, Denmark.

<sup>k</sup> Inserm U987, AHP, UVSQ, Paris-Saclay University, Ambroise Pare Hospital, Boulogne-Billancourt, France.

<sup>l</sup> Institute of Psychiatry, Psychology & Neuroscience, Department of Basic & Clinical Neuroscience, Division of Neuroscience, King's College London, London, UK.

<sup>m</sup> Parkinson Foundation Centre of Excellence in Care and Research, King's College Hospital NHS Foundation Trust, London, UK.

<sup>n</sup> Department of Neurophysiology, Mannheim Center for Translational Neurosciences, Heidelberg University, Mannheim, Germany.

\*\*Both authors contributed equally to this work

**Number of pages: 28**

**Number of figures: 1**

**Number of tables: 0**

**Corresponding author:** Daniel Ciampi de Andrade

Mailing address: Centre for Neuroplasticity and Pain (CNAP),

Department of Health Science and Technology, Faculty of Medicine, Aalborg University,

Office 12.02.018. Selma Lagerlöfs Vej 249, 9260. Gistrup, Danmark

E-mail: dca@hst.aau.dk

## Abstract

Parkinson's disease (PD) affects up to 2% of the general population older than 65 years and is a major cause of functional loss. Chronic pain is a common non-motor symptom that affects up to 80% of patients with (Pw) PD both in prodromal phases and during the subsequent stages of the disease, negatively impacting patient's quality of life and function. Pain in PwPD is rather heterogeneous and may occur due to different mechanisms. Targeting motor symptoms by dopamine replacement or with neuromodulatory approaches may only partially control PD-related pain. Pain in general has been classified in PwPD according to the motor signs, to pain dimensions or to pain subtypes. Recently, a new classification framework focusing on chronic pain was introduced to group different types of PD-pains according to mechanistic descriptors: nociceptive, neuropathic, or neither nociceptive nor neuropathic. This is also in line with the International Classification of Disease-11, which acknowledges the possibility of chronic secondary musculoskeletal/nociceptive pain due to disease of the CNS. In this narrative review and opinion article, a group of basic and clinical scientists revise the mechanism of pain in PD and the challenges faced when classifying it as a steppingstone to discuss an integrative view of the current classification approaches and how clinical practice can be influenced by them. Knowledge gaps to be tackled by coming classification and therapeutic efforts are presented, as well as a potential framework to address them in a patient-oriented manner.

**Keywords:** Parkinson disease, rigidity, chronic pain, neuropathic pain, musculoskeletal pain, secondary pain, dopamine, deep brain stimulation.

## INTRODUCTION

### Recent advances in the classification of pain disorders

From a medical and pragmatic perspective, classification of mechanisms, syndromes, phenotypes, or diseases serves to group individuals in terms of similar prognostic or treatment response profiles. By doing so, the expected natural history and progression of a person's medical condition may be delineated, enabling more assertive and direct management. In the last years several new important steps have been made to improve the classification of chronic pain disorders (i.e., pain present for most days for more than 3 months) [111,137]. On one hand, an enormous taxonomy effort was undertaken by the International Association for the Study of Pain (IASP) and the International Classification of Diseases-11 (ICD-11) working groups to provide a framework to classify pain disorders into primary and secondary categories, with subsequent subclassifications introducing the concept of primary pain syndromes [76,100,105,128]. It also acknowledged the possibility of non-neuropathic pains caused by neurological diseases (e.g., chronic secondary musculoskeletal pain due to disease of the CNS – MG30.32). Additionally, the ICD-11 introduced the option to individualize pain assessment based on the use of extension codes covering pain intensity, pain-related distress, interference, and presence of different psychosocial factors such as catastrophizing, fear, anger, avoidance, and negative interferences of pain on work and interpersonal relationships.

On the other hand, the classification of pain into mechanistic descriptors was updated, by adding a third mechanistic descriptor to the traditional nociceptive and neuropathic pain subtypes [42,65]: the term nociplastic pain was suggested to replace “idiopathic pain” for instances where pain was neither nociceptive nor neuropathic, and a grading system for nociplastic pain has also been proposed [63]. It is therefore currently possible to categorize a patient's pain according to the ICD-11 framework for classification purposes, while also acknowledging its putative mechanisms. However, the improvement in classification and communication of pain disorders brought about by the new taxonomy frameworks remains challenging. This is especially true in instances where pain and sensory symptoms can worsen over time due to neurodegeneration, or be markedly influenced by treatment, such as in the case of Parkinson's disease (PD) [92]. As also seen in dystonia, and lateral amyotrophic sclerosis, for example, a disease of the motor system can cause pains that are not simply of musculoskeletal mechanisms, because diseases process leading to motor impairment may also affect pain integration or pain modulatory networks.[73,78] This is also valid for systemic disease, which may affect motor and somatosensory systems in different proportions leading to different types of pain syndromes[5,67,87,89,112,130] .

98

99 **Pain as a non-motor symptom of Parkinson's disease**

100 Motor parkinsonism (also known as akinetic-rigid syndrome) is defined by the presence of bradykinesia  
101 (i.e., the slowness and decrement in amplitude or speed of movement) in combination with rigidity (i.e.,  
102 the increased muscle tonus upon slow passive movement of major joints), rest tremor (i.e., 4 to 6 Hz  
103 tremor in the fully resting limb, which is frequently suppressed during movement initiation), or both.  
104 There are several causes of parkinsonism, such as drug-related, traumatic brain injury, neuro-infection,  
105 and neurodegeneration, among others. The most prevalent cause of parkinsonism is  
106 neurodegeneration, headed by Parkinson's disease (PD) among its several aetiologies. Motor  
107 symptoms in PD are asymmetric and usually very responsive to dopamine replacement therapy, at least  
108 initially.

109 Despite being recognised by James Parkinson and others [49,51,70,107,119,138], non-motor  
110 symptoms (NMS) in PD received less attention than motor ones for many decades. Initially thought to  
111 be synonymous with non-dopaminergic symptoms and considered to be present only in initial phases  
112 of the disease, it soon became clear that non motor symptoms were prevalent during all stages of PD  
113 and may have dopaminergic or non-dopaminergic mechanisms. NMSs are acknowledged to pose a  
114 heavy burden on patient's quality of life and include chronic pain, sleep and impulse control disorders,  
115 mood symptoms, cognitive dysexecutive complaints, olfactory loss, constipation, and urinary urge-  
116 incontinence, among others. Importantly, non-motor symptoms occur due to disease affecting multiple  
117 organs and systems and are not all dependent on dopaminergic modulation  
118 [15,29,30,34,86,120,142,144,145].

119 The general premise is that a single disease (PD) may cause different types of symptoms because it  
120 may disrupt different types of physiological functions or networks in different patients, according to  
121 individual susceptibility profiles [9,33,55,88]. For instance, some PD patients may present with tremor-  
122 predominant disease, while about one third will not present with incapacitating rest tremor [2,88,108]  
123 during disease evolution. The "disease" is the same in both instances, but its interaction with the  
124 individual leads to different neuronal networks or functions to be affected in a unique manner, with  
125 different mechanistic abnormalities giving rise to diverse clinical manifestations. The same occurs with  
126 NMS such as pain [114]. PD may cause pain via different mechanisms in different patients, and these  
127 mechanisms may or may not be related to a) altered motor control (e.g., rigidity) and b) altered  
128 dopaminergic signalling. Proper diagnostic classification of these multiple different types of pain in PD  
129 may seem like an academic exercise, but it will become highly relevant when clinical assessment and  
130 auxiliary exams can identify the pain type such that specific management may proceed.

It has been shown that pain in PD may on one hand be musculoskeletal (i.e., nociceptive), on the other hand may have characteristics of central neuropathic pain or may have to be labelled “other chronic pain” (“unspecified in ICD-11, “nociplastic” characteristics according to the IASP’s mechanistic descriptors). Such differentiations may be strategic in determining prognosis and treatment options [42,43,57,97,110]. In parallel to all these possibilities, pain can also be classified according to the motor state of patients and the effect of dopamine-replacement therapy at the moment pain is assessed [110] or according to “PD-pain domains” [16]. All the above possibilities and different combinations of pain occurrence and mechanistic backgrounds may combine to give rise to several varieties of motor and pain presentations seen in clinical practice [4,24,80,81]. Currently, different questionnaires, scales, classification frameworks and systems have been proposed to cover each of these different approaches. The present text aims to critically review and to propose an integrative approach of the current classification schemes for pain in patients with Parkinson’s disease (PwPD). This consolidative view may help basic scientist and clinicians to make the best out of the current evidence and improve research design and patient care.

## METHODS

The search strategy included the databases MEDLINE (through PubMed), Web of Science, and EMBASE, which were screened since inception until March 2023. Conference proceedings were not included. Historically relevant books and reports were included and reference list from major research papers and reviews were screened and used when necessary. The International Classification of Diseases (ICD) -11 website and the International Association for the Study of Pain (IASP) definitions list and classification frameworks were also consulted and searched for. Search strings blended Parkinson (’s) disease and pain, and related terms such as parkinsonism, nociception, treatment, analgesia, chronic pain, questionnaire, and scale. Original studies, reviews and white papers were included if they provided relevant information related to chronic pain definition, mechanisms of specific chronic pain etiologies such as musculoskeletal pain, mechanistic information about chronic pain mechanistic descriptors. Studies reporting somatosensory, intraepidermal nerve fiber density counting, or pain thresholds in chronic pain in patients with Parkinson’s disease were included. Studies assessing the effects of motor treatment based on dopamine replacement (e.g., levodopa, apomorphine) and deep brain stimulation in

pain and sensory thresholds in patients with Parkinson's disease (PwPD) were included, along with efforts to assess and validate general pain assessment tools in PwPD, and effort to create new pain classification, scales and questionnaires in PD. Relevant information related to the interplay of the somatosensory system and the basal ganglia, as well as the relationship between the basal ganglia and nociception and pain processing were included when relevant. When available, official sources of data and definitions such as the IASP, the Movement Disorders Society and the ICD-related publications were privileged. Literature review was initially conducted by DCA and VM, and all co-authors contributed to it with subsequent updates or additions. The manuscript has the first draft made by VM and DCA and several online and written electronic exchanges were performed with all authors for discussion and development of the final version of the manuscript.

## **RESULTS**

### **Pioneering classification attempts of pain in PD**

Detailed attempts have been made to classify pain in PD and provided an invaluable framework and important insights into PD physiology. Quinn et al. [110], were among the first to provide a comprehensive classification scheme of pains in PD according to the motor status of patients. They described four scenarios in a clinical case-based format and were among the first to acknowledge a very important aspect of pain in PD: levodopa intake would at least partially improve pain associated with non-motor off symptoms such as anxiety or depressive spells, irrespective of the motor state patients were in. This supported the currently evolving concept that motor and the different dopamine-responsive non-motor symptoms may present different levodopa levels thresholds for their control. Therefore, patients with pain fluctuations may benefit from levodopa adjustments even when control of motor symptoms is already optimised [58,120,139–141]. Several arguments support that dopamine replacement therapy adjustments should be the first attempt when caring for PD patients with non-motor symptoms. While this strategy is not backed up by strong clinical evidence, it is supported by long-term clinical experience and experimental data [6,7,12,15,21,28,47,136].

Later, Ford [44,45] proposed a classification of pain in PwPD into five categories: i. musculoskeletal pain, ii. radicular/neuropathic pain, iii., dystonia, iv., central or primary pain, v. akathisia pain. This approach can be challenging for non-specialists in pain and movement disorders because it includes pains classified according to diseases/aetiologies (primary pain, MSK pain, radiculopathy), with pains

based on syndromes (neuropathic pain), and also pains based on motor findings (dystonia, akathisia). Moreover, the use of “central” as a synonym for “primary” is misleading: central should refer to CNS diseases, while in primary pain there is no underlying disease and chronic pain itself is the disease[101]. It is known today that these instances of pain are not mutually exclusive and that different aetiologies of pain may share the same mechanistic background. Furthermore, this framework concerns present pain, and no information is provided about pain recurrence or chronicity. However, Ford clearly acknowledged that if musculoskeletal (MSK) pain has no apparent cause, PD dopamine-based treatment adjustments should be tried, in line with views that pain is a non-motor symptom that may fluctuate independently of motor ones, and that dopamine acts as a potential modulator of nociceptive processing in PD patients. He also proposed that PD patients may have neuropathic pain, which he called “radicular and neuritic” pains. While not all radiculopathies are associated with pain, and while other aetiologies of neuropathic pain may exist in PD apart from nerve root abnormalities, detecting neuropathic pain in PD has therapeutic implications.

Following Souques, who described instances of diffuse, unexplained migrating pain in PD patients as affecting areas not commonly affected by MSK or dystonic pain such as the abdomen or genitalia [119], Ford proposed that PD patients could have “central or primary pains”. He acknowledged that these patients would often experience pains in episodes of restlessness, obsessional, and distressing spells, associated with autonomic changes and visceral sensations, that would commonly overshadow their classic motor complaints. He reported that these pains may not respond to levodopa increases, and that their therapeutic control was challenging. Whether this pain should be called “primary” is questionable, since they are associated to PD. It is acknowledged that the majority of PwPD have musculoskeletal pain, but there are also non-musculoskeletal pains possibly associated with dopamine dysregulation syndrome. These have received different labels, often alluding to some “central” mechanisms[25].

### **Not all pains due to central diseases are central neuropathic pain.**

There is little doubt that “central” alterations in nociceptive processing tend to occur to some extent in all people with acute or chronic pain[123,124]. Thus “central” plastic changes do not discriminate between different types of pain [24,27]. However, there is a clear definition of what constitutes central neuropathic pain. IASP and WHO have defined neuropathic pain as pain due to lesion or disease of the somatosensory nervous system, and for central neuropathic pain such lesions or diseases affect the somatosensory system components in spinal cord, brainstem, thalamus, or cortex. Although the striatum and *globus pallidus* are part of the extrapyramidal motor system, there is evidence that some of their functional loops subserve non-motor functions, including nociceptive signal processing in the putamen

in experimental animal and human studies [10,17–19,59,74,134]. Thus, PwPD may be considered to suffer from central neuropathic pain. According to the grading system [40,77,126], the next question is if pain distribution is consistent with the receptive fields of the somatosensory system structure. Like for cortical stroke, this question is difficult to answer for basal ganglia; in principle, hemibody or quadrant pain would be consistent with “possible neuropathic pain”. To reach the level “probable neuropathic pain, some sensory signs must be present in the painful region. Lesions to the basal ganglia do not easily correlate with abnormalities in the sensory clinical exam, as they do not clearly lead to sensory deficits. Also, data from dystonic patients show that deep brain stimulation to these structures do not influence sensory thresholds [74,75]. This means that the clinical picture of lesions or disease to these structures may not lead to a pain type that clinically has sensory findings like other neuropathic pain. Thus, whether “central” in Ford’s classification may imply “central neuropathic pain” is still questionable and challenged. One would probably need to (re)define what constitutes a sensory sign in PD; possibly analogous to the redefinition of triggered attacks as sensory signs of trigeminal neuralgia that has traditionally been thought to be neuropathic although most patients have neither sensory deficits nor gains [5,27]. In “central PD pain”, while pain may have descriptors such as tingling or burning character [39,41,61], the sensory examination does not provide signs that would confirm the location of the lesion to the somatosensory system (i.e., basal ganglia). In fact, pain in PD was reported to occur more commonly axially, in the lower back, shoulders and neck, and its relief not to correlate with motor or somatosensory changes after treatment [20,24].

In Ford’s classification, central pain patients had complex neuropsychiatric manifestations, and frequently complained of pain in a context of what would be classified today as either dopamine dysregulation syndrome, dopamine agonist withdrawal syndrome or non-motor offs, so that pain in this situation is just one of the several symptoms dominating the clinical picture. Thus, the term “central” in Ford’s classification may be interpreted to refer to the concepts of “central sensitization like pain” [102] or “nociplastic pain” [66]. Although central sensitization is usually referred to spinal signal processing, sensitization at cortical levels would explain the comorbidity of chronic pain with anxiety and depression [124]. Further supporting the idea that Ford’s “central pain is not central neuropathic pain”, Marques et al. [80,82] suggested these pains would fulfil the definition of “nociplastic” pain in the sense of being non-nociceptive and non-neuropathic.

#### **Validated assessment tools for pain in PwPD.**

In the first systematic review evaluating the use of general pain scales and questionnaires in PD patients, Perez-Lloret et al., 2016 [109] found several studies reporting on the use of classic pain

questionnaires such as the douleur neuropathique-4, the brief pain inventory, and McGill pain questionnaire (short-form) [37] to characterise pain in PwPD. At that point, these tools had not yet been fully validated for use in PD, thus leading to the Movement Disorders Society Committee on Rating Scales to recommend for their use with caution. In the following years, most of these tools were eventually specifically tested in PD patients and their clinometric properties were granted for these patients. Lately, a specific pain assessment tool was developed to characterise pain occurring within the previous month without any clear cause and judged to be caused by PD by the clinician. The Kings Parkinson's disease Pain Scale [16] (KPPS) proposed the subdivision of PD-related pains into 7 "domains". These 7 pain domains consist of musculoskeletal, central, fluctuation-related, nocturnal, orofacial, burning pain in the limbs with oedema and swelling and radicular pain. It remains to be determined whether the KPPS seven domains represent specific clinical entities or markers of specific pain mechanisms. Active research is being performed to create treatment strategies specifically designed to these domains which would provide new personalized strategies to treat specific subdomains of pain in PD [68]. Quinn's, and Ford's classifications concerned any pain event in PwPD, not necessarily chronic pain, while the King's scale concerns pain directly related to PD (no explainable cause other than PD) lasting for more than 1 month. Up to 60% of PwPD will present pain most of the days and lasting for more than 3 months (ie, chronic pain), which may impact quality of life as much as motor symptoms and is a major unmet need in the management PwPD.

To fill in this gap, several groups have proposed to classify chronic pain directly related to PD according to the IASP mechanistic descriptors of pain. It was argued that such classification system could be used along with other motor status or domain-based classifications systems, and also to disease-oriented classification systems such as the ICD-11. PwPD presenting with chronic pain had their pains classified as nociceptive, neuropathic or nociplastic. In nociceptive pain, nociceptors are activated by mechanical, thermal, or inflammatory stimuli related to actual or potential lesions of non-neural tissue. This pain type includes the musculoskeletal (MSK) pain syndromes, such as osteoarthritis, and other chronic conditions where tissue lesions and/or inflammation predominates. Neuropathic pain is defined as being directly due to a lesion or disease of the peripheral or central somatosensory system [127]. In the neuropathic pain grading system, history and physical examination allow for the diagnosis of "possible neuropathic pain", while "probable" and "definite" neuropathic pain require evidence for location (neurologically plausible sensory signs) and nature of the lesion [41]. "Nociplastic" pain mechanistic descriptor comprise instances where the nociceptive system is overactive without any evidence of somatosensory system lesion or peripheral activation of nociceptors [65]. Although not yet applied to

292 PD, a recent grading system proposed an algorithm to propose positive evidence for an overactive  
293 nociceptive system in potentially nociplastic pains [63].

294 The IASP mechanistic classification system was tested in PwPD recently [97]. PD-related pain was  
295 proposed as present if: i. pain started or became more severe after the initiation of motor symptoms of  
296 PD, ii., pain was aggravated by motor slowness or rigidity, iii., pain was associated with excessive  
297 involuntary movements; iv., pain was improved by dopaminergic drugs [93,135]. Seventy-seven percent  
298 of patients with PD and chronic pain had PD-related pain (either aggravated by PD or directly associated  
299 with PD) [93,135]. Once PD related pain was determined, patients filled in the Douleur Neuropathique-  
300 4 (DN-4) questionnaire [92], including items on patient examination. Patients with a positive DN4 were  
301 considered as being positively screened for neuropathic pain, which was present in 16% of PD pain  
302 patients. If it was negative, signs of off-period pain, dystonia pain, or peak-of-dose pains, with muscle  
303 soreness and regional or localised pain upon palpation of tendons or fascia, could be classified as  
304 nociceptive pain. This was the most common pain mechanism affecting 55% of the sample. Those not  
305 fulfilling DN-4 positivity or nociceptive criteria were considered as having “nociplastic” pain (in the sense  
306 of being non-nociceptive and non-neuropathic) and in these cases dysautonomia features, anxiety and  
307 dysphoria, non-motor off fluctuations and behavioural mood oscillation predominated. Such “nociplastic”  
308 pain occurred in 22% of the sample. After this publication, an effort to provide a grading system for  
309 nociplastic MSK pain was proposed and awaits validation[64]. Using this system most patients would  
310 not reach the level “possible nociplastic pain” because this requires the presence of documented  
311 positive sensory signs.

312

### 313 Pain phenotypes in Parkinson’s disease

314 Although not based on the grading system for neuropathic or nociplastic pains a simple mechanistic  
315 classification using previously proposed definitions was able to segregate patients with different clinical  
316 profiles. For example, “nociplastic” pain was associated with widespread pain, affecting on average 10  
317 body locations (which is actually a criterion from the grading system for nociplastic pain), in contrast with  
318 nociceptive pain, which was more localised, more fluently affecting the trunk[71], and being present in  
319 average on 4.8 body locations [97]. Pains with possible neuropathic pain according to screening had  
320 more intense pain compared to the other two mechanisms, while “nociplastic” pain was associated with  
321 more sensory and affective descriptors of pain and had less levodopa-induced dyskinesia. Additionally,  
322 a principal component analysis confirmed that the three different pain mechanisms had a distinct  
323 distribution within the factors.

In these classification systems an operational definition of pain with neuropathic pain descriptors was based on the positivity of a screening questionnaire, which only allow for the diagnosis of “possible” neuropathic pain in PD. One of the few studies using in-person validated criteria for neuropathic pain found that 6.9% of PD patients had definite neuropathic pain [24,41], which is close to the prevalence in the general population. Moreover, neuropathic pain was markedly unresponsive to deep brain stimulation, and all patients with neuropathic pain had a disease to the somatosensory system other than PD [24,41].

Like the IASP/ICD-11 pain classification, the mechanistic classification of pain in PD can be performed in parallel to other aetiology, situational, or domain-based classifications, such as those reported by the King's Parkinson's disease pain questionnaire [16], Ford's [44] or Quinn's [110] pain classification systems (Figure 1).

One developing perspective to non-motor symptom classification in PD is endophenotyping. While motor subtype classification of PD has been shown to be unstable over time, recent work focussing on non-motor endophenotyping seem promising. Initial descriptions included PD pain as a specific subtype which included unexplained lower limb pain syndromes commonly seen in moderately advanced PD [48,83,113,133]. Further work suggests that PD pain segregates into a noradrenergic subtype of PD which could also carry implications on personalised medicine and subtype specific treatment strategies for pain in PD [84].

## DISCUSSION

### PD somatosensory “gain” and its impact in pain classification

Experimental studies have demonstrated that dopamine D<sub>2</sub> receptors participate in the modulation of nociceptive signals centrally both at the striatum, and at the spinal cord via hypothalamic A11 descending projections to the spinal cord. It has also been shown that motor neuromodulatory interventions depend on these receptors to provide pain relief in models of neuropathic pain [1,56,132]. In healthy humans, low density of D2 receptors is associated with cold pain thresholds increase and defective descending pain modulatory activity [85,122]. Initial reports using quantitative sensory testing have suggested that PwPD had lower [99,104] and higher [20,104] pain thresholds compared to age-matched healthy individuals. These contradictory results could be due to the fact that using reaction time-based approaches to determine thresholds in a disease with asymmetric motor signs could be a source of bias. Additionally, one marked peculiarity of PD is that several somatosensory channels are

357 influenced by the treatment status on the time of data collection, be it pharmacological (levodopa,  
358 dopamine agonists) or neuromodulatory (DBS), which requires standardization and report on whether  
359 patients were in the On or Off treatment condition when assessments were made. Later studies with  
360 larger sample sizes, in which medication intake was controlled for, and using reaction time-independent  
361 quantitative sensory testing methodologies have suggested that mechanical, cold and heat pain are in  
362 fact lower than the expected for age [12,20,26,53,54,72,117,131] in PwPD. So, it is believed that  
363 irrespective of the presence of chronic pain, PwPD have lower pain thresholds both during the Off and  
364 On medication states (i.e., when the effect of dopamine replacement therapy medication wears off, or  
365 when it is adequate, respectively) when compared to healthy age- and sex-matched controls  
366 [11,20,26,27,92,94]. It has also been shown that sensory detection abnormalities may exist in patients  
367 with idiopathic rapid eye movement sleep disorder, considered to be potentially prodromal of PD  
368 [62,121] in a significant proportion of cases, as well as in patients in early stages of PD, before levodopa  
369 was started and additionally suggested to progress as disease advances [60,92]. *De novo* pain in PD  
370 has been reported as being partially influenced by levodopa administration, which generally does not  
371 affect pains unrelated to PD [28,110]. Additionally, PD-related pains are more common during off  
372 episodes (i.e., when patients stop medication or neuromodulatory treatment). Like other non-motor  
373 symptoms, PD-related pain may be aggravated/appear when patients experience non-motor Offs,  
374 commonly leading to accompanying mood and behavioural abnormalities [50].

375 MSK pain in PwPD has historically thought to be due to muscle rigidity. Indeed, the musculogenic theory  
376 initially proposed that pain in PD was mainly due to the presence of increased motor tonus [118], which  
377 would lead to muscle contractures and pain. This theory as the sole explanation for pain in PD was  
378 challenged by the finding that chronic pain is common in early disease stages [35] when motor  
379 symptoms are still incipient, and that although pain improvement may occur after levodopa therapy or  
380 deep brain stimulation, their subsequent analgesic effects are not correlated with motor improvement  
381 [24,79]. It was also shown that even pain-free patients would present quantitative sensory test signs of  
382 “gain” in sensory processing [143]. Furthermore, pain may also occur along with excessive movements,  
383 as is the case of choreiform dyskinesias, when levodopa levels are thought to be high [23,110].  
384 Together, these data suggest that pain in PwPD may not exclusively be due to peripheral generators of  
385 pain such as motor rigidity but would also be influenced by an intrinsic state of allodynia and  
386 hyperalgesia potentially maintained by dysfunctional somatosensory processing, possibly at the basal  
387 ganglia[14,27].

388 PD patients in moderate or advanced phases of the disease have marked nigrostriatal degeneration,  
389 which leads to a lower storage capacity of dopamine in axonal terminations from the substantia nigra

reaching the striatum [52]. When dopamine replacement therapy is initiated, dopamine storage fluctuates according to blood levels of medication, leading to oscillations in motor control, which can rise from a low (rigidity, slowness of movement) to an excessive dopaminergic synaptic availability (hyperkinetic choreiform dyskinetic movements) in minutes. These motor oscillations are a hallmark of moderate/advanced disease, and their treatment, when refractory, requires specific medication or neuromodulatory interventions. It was reported that non-motor symptoms that are partially dependent on dopamine such as mood and pain would also oscillate according to dopamine storage in the striatum. The subsequent non-motor On's and Off's do not necessarily correlate with motor oscillations. This means that patients on a relatively stable and controlled motor symptoms, may experience non-motor symptom oscillations due to different needs and sensitivities to dopamine level oscillations in non-motor cortico-striato-thalamo-cortical loops. Indirect evidence suggests that PD-related pain would also present oscillations due to non-motor Offs. This is supported by clinical experience and by studies showing that motor control after pharmacological or neuromodulatory treatment is dissociated from pain relief. Sensory oscillations can be captured by non-motor symptom questionnaires in clinical and research settings [15]. Reports suggest that patients with pain should request adjustments in their dopamine replacement therapy slightly above the dosage necessary to relieve motor symptoms [36,88,120,141]. This concept is further supported by the occurrence of dopamine agonist withdrawal syndrome, which refers to the emergence of fatigue, cognitive complaints, and diffuse widespread pain in patients who have good motor control, and in whom a decrease in dosage of dopamine agonists is attempted [103,110]. Patients tolerate dosage reduction from the motor perspective but cannot bear the new onset of symptoms associated with dopaminergic medication tapering.

#### **Practical issues when assessing and managing pain in PwPD.**

The examination of patients with PD and rigidity with pain frequently reveals tender joints, sensitive fascia and entheses and muscle pain upon gentle palpation that would not otherwise hurt [24]. These points would argue that pain associated with rigidity has nociceptive characteristics and that soft tissue injuries are clearly driving pain [71,90,91,97]. It was later acknowledged that patients at an early stage of the disease would present intense pain, despite having low levels of rigidity [35]. Also, interventions known to ameliorate motor symptoms, rigidity included, may also improve pain, but in these instances pain improvement is not necessarily correlated to rigidity control [24,34,145]. It means that in instances of rigidity and pain, it is usually not possible to ascertain that pain is specifically caused by rigidity, and not by another peripheral nociceptive driving factor that is centrally augmented. So, in a pragmatic approach, the finding of rigidity and pain could classify pains as nociceptive, thus acknowledging that

423 MSK system is to some degree contributing to the occurrence of pain as a peripheral pain generator  
424 being centrally over-amplified [71,125].

425 As mentioned above, a common challenge is the determination of lesion to the somatosensory system  
426 in PD when attempting to diagnose neuropathic pain in PwPD. Studies assessing intraepidermal nerve  
427 fiber density by PGP9.5 staining showed that PD leads to major small fibre denervation [31,104]. It was  
428 additionally later described that extranigral, extra-cephalic Lewy body neuronal deposition[32,104] could  
429 also be detected in sensory afferents in the skin. However, small-fibre intra-epidermal decrease, also  
430 called small fiber pathology, is also found in a long list of other neurological diseases, and their functional  
431 meaning is debatable. To date, it has never been shown in PwPD that these changes occur on body  
432 areas where pain is present. Furthermore, sensory gain and loss of function in PD may be significantly  
433 impacted by intake of levodopa or deep brain stimulation, suggesting that changes are rather dynamic.  
434 Changes in somatosensory gain are likely to be influenced by functional oscillatory activity at a network  
435 level, rather than solely relying on hard-wired structural neurodegeneration [3,27,38,106]. This creates  
436 a situation when neuropathic pain would only be diagnosed as “definite” according to the revised grading  
437 systems if clear sensory signs could be identified and characterized, similar to triggered attacks in  
438 trigeminal neuralgia [22,129]. On the other hand, in the absence of a clear pain distribution compatible  
439 with lesion to classic somatosensory structures, a neuropathic pain directly related to PD, if it is proven  
440 to exist, could only reach the “possible” degree of diagnostic certainty. Some have chosen to use  
441 positivity of screening tools for neuropathic pain such as the Douleur Neuropathic-4 for identifying PwPD  
442 with neuropathic pain components [46]. These strategies have revealed that around 1/5 of chronic pain  
443 PwPD have positivity in screening tools. While these patients should not be called “definite” neuropathic  
444 pain patients, they do fulfil the diagnosis of possible neuropathic pain. The screening questionnaire-  
445 based classification has been shown to allow for the classification of PwPD and pain with clinically  
446 different profiles and characteristics, which are likely to be related to different mechanisms of disease  
447 and respond differently to treatment [97]. Attempts to comprehensively characterize the extent of the  
448 somatosensory system and what comprises a neuroanatomically plausible sensory sign in future may  
449 help shed light to these instances.

#### 450 451 **Implications of the current knowledge to the care of PwPD with pain**

452 Pain in general is ominous in PwPD. It can be classified according to motor status as proposed by  
453 Quinn, according to Ford’s framework or according to pain subtypes, by using the KPPS (Figure 1).  
454 Chronic pain, in particular, is also very prevalent in PwPD and may not respond to treatments aimed at  
455 motor control. Chronic pain may be unaffected and unrelated to the disease (i.e., PD-unrelated pain) or

456 affected by/related to it (i.e., PD-related pain). Although the distinction between nociplastic and  
457 neuropathic pains could not be made according to the grading systems, the tentative mechanistic  
458 classification allowed for the segmentation of patients with different pain characteristics and associated  
459 symptoms and were able to select responders to specific treatment approaches[69,71]. To date, solid  
460 evidence-based treatment for chronic pain in PD is lacking [95,115,116] or poor. When clinically possible  
461 and safe, there is a general agreement to try small increases in dopamine-replacement therapy as a  
462 therapeutic test in instances of pain directly related to PD, even when motor control is optimized. Recent  
463 studies are to incorporate patients' selection based on different pain types or discrete endophenotypes  
464 in clinical trials to treat chronic pain in PwPD and are promising [68]. The advances in classification  
465 presented here are likely to improve treatment towards distinct types of pain in PD in the future, but they  
466 also reveal some general classification and mechanistic gaps that need to be refined in coming  
467 translational multidisciplinary efforts.

468  
469  
470

471   ACKNOWLEDGEMENTS

472   The authors have no conflicts of interest to disclose. The Center for Neuroplasticity and Pain (CNAP)  
473   is supported by the Danish National Research Foundation (DNRF121). DCA is supported by a Novo  
474   Nordisk Grant NNF21OC0072828, and European Research Council grant 101087925. NBFs work in  
475   neuropathic pain is supported by the Lundbeck Foundation (R359-2020-2620)

476

477

## References

- [1] Ansah OB, Leite-Almeida H, Wei H, Pertovaara A. Striatal dopamine D2 receptors attenuate neuropathic hypersensitivity in the rat. *Exp Neurol* 2007;205:536–546. doi:10.1016/J.EXPNEUROL.2007.03.010.
- [2] Asch N, Herschman Y, Maoz R, Auerbach-Asch CR, Valsky D, Abu-Snineh M, Arkadir D, Linetsky E, Eitan R, Marmor O, Bergman H, Israel Z. Independently together: subthalamic theta and beta opposite roles in predicting Parkinson's tremor. *Brain Commun* 2020;2. doi:10.1093/BRAINCOMMS/FCAA074.
- [3] Ballarini T, Růžicka F, Bezdicek O, Růžicka E, Roth J, Villringer A, Vymazal J, Mueller K, Schroeter ML, Jech R. Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinson's disease patients. *Sci Rep* 2018;8.
- [4] Bannister K, Smith R V., Wilkins P, Cummins TM. Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing. *NPJ Parkinsons Dis* 2021;7. doi:10.1038/S41531-021-00173-Y.
- [5] Barbosa LM, da Valerio F, Pereira SLA, da Silva VA, de Lima Rodrigues AL, Galhardoni R, Yeng LT, Rosi J, Conforto AB, Lucato LT, Lemos MD, Teixeira MJ, de Andrade DC. Site matters: Central neuropathic pain characteristics and somatosensory findings after brain and spinal cord lesions. *Eur J Neurol* 2023;00:1–10. doi:10.1111/ENE.15744.
- [6] Battista AF, Wolff BB. Levodopa and induced-pain response. A study of patients with Parkinsonian and pain syndromes - PubMed. *Arch Intern Med* 1973;132:70–74. doi:10.1001/archinte.1973.03650070062009.
- [7] Becker S, Gandhi W, Elfassy NM, Schweinhardt P. The role of dopamine in the perceptual modulation of nociceptive stimuli by monetary wins or losses. *Eur J Neurosci* 2013;38:3080–3088. doi:10.1111/EJN.12303.
- [8] Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson's disease: Prevalence and characteristics. *Pain* 2009;141:173–177. doi:10.1016/J.PAIN.2008.12.004.
- [9] Berman BD, Smucny J, Wylie KP, Shelton E, Kronberg E, Leehey M, Tregellas JR. Levodopa modulates small-world architecture of functional brain networks in Parkinson disease. n.d.
- [10] Bernard JF, Huang GF, Besson JM. Nucleus centralis of the amygdala and the globus pallidus ventralis: electrophysiological evidence for an involvement in pain processes. *J Neurophysiol* 1992;68:551–569. doi:10.1152/JN.1992.68.2.551.
- [11] Boura E, Stamelou M, Vadasz D, Ries V, Unger MM, Kägi G, Oertel WH, Möller JC, Mylius V. Is increased spinal nociception another hallmark for Parkinson's disease? *J Neurol* 2017;264:570–575. doi:10.1007/S00415-016-8390-Y.
- [12] Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. *Mov Disord* 2005;20:1557–1563. doi:10.1002/MDS.20629.
- [13] Broen MPG, Braaksma MM, Patijn J, Weber WEJ. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. *Mov Disord* 2012;27:480–484. doi:10.1002/MDS.24054.

- 519 [14] Caspers J, Rubbert C, Eickhoff SB, Hoffstaedter F, Südmeyer M, Hartmann CJ, Sigl B, Teichert N,  
520 Aissa J, Turowski B, Schnitzler A, Mathys C. Within- and across-network alterations of the  
521 sensorimotor network in Parkinson's disease. *Neuroradiology* 2021;63:2073–2085.  
522 doi:10.1007/S00234-021-02731-W.
- 523 [15] Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis  
524 and management. *Lancet Neurol* 2006;5:235–245. doi:10.1016/S1474-4422(06)70373-8.
- 525 [16] Chaudhuri KR, Rigos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-  
526 Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, Antonini A, Martinez-  
527 Martin P. King's Parkinson's disease pain scale, the first scale for pain in PD: An international  
528 validation. *Mov Disord* 2015;30:1623–1631. doi:10.1002/MDS.26270.
- 529 [17] Chudler EH. Response properties of neurons in the caudate-putamen and globus pallidus to  
530 noxious and non-noxious thermal stimulation in anesthetized rats. *Brain Res* 1998;812:283–  
531 288. doi:10.1016/S0006-8993(98)00971-8.
- 532 [18] Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. *Pain* 1995;60:3–38.  
533 doi:10.1016/0304-3959(94)00172-B.
- 534 [19] Chudler EH, Sugiyama K, Dong WK. Nociceptive responses in the neostriatum and globus  
535 pallidus of the anesthetized rat. *J Neurophysiol* 1993;69:1890–1903.  
536 doi:10.1152/JN.1993.69.6.1890.
- 537 [20] Ciampi De Andrade D, Lefaucheur JP, Galhardoni R, Ferreira KSL, Brandão Paiva AR, Bor-Seng-  
538 Shu E, Alvarenga L, Myczkowski ML, Marcolin MA, De Siqueira SRDT, Fonoff E, Barbosa ER,  
539 Teixeira MJ. Subthalamic deep brain stimulation modulates small fiber-dependent sensory  
540 thresholds in Parkinson's disease. *Pain* 2012;153:1107–1113. doi:10.1016/J.PAIN.2012.02.016.
- 541 [21] Coffeen U, López-Avila A, Ortega-Legaspi JM, del Ángel R, López-Muñoz FJ, Pellicer F. Dopamine  
542 receptors in the anterior insular cortex modulate long-term nociception in the rat. *Eur J Pain*  
543 2008;12:535–543. doi:10.1016/J.EJPAIN.2007.08.008.
- 544 [22] Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, Treede RD, Zakrzewska JM,  
545 Nurmikko T. Trigeminal neuralgia: New classification and diagnostic grading for practice and  
546 research. *Neurology* 2016;87:220–228. doi:10.1212/WNL.0000000000002840.
- 547 [23] Cury RG, Galhardoni R, Fonoff ET, Perez Lloret S, Dos Santos Ghilardi MG, Barbosa ER, Teixeira  
548 MJ, Ciampi De Andrade D. Sensory abnormalities and pain in Parkinson disease and its  
549 modulation by treatment of motor symptoms. *Eur J Pain* 2016;20:151–165.  
550 doi:10.1002/EJP.745.
- 551 [24] Cury RG, Galhardoni R, Fonoff ET, Dos Santos Ghilardi MG, Fonoff F, Arnaut D, Myczkowski ML,  
552 Marcolin MA, Bor-Seng-Shu E, Barbosa ER, Teixeira MJ, De Andrade DC. Effects of deep brain  
553 stimulation on pain and other nonmotor symptoms in Parkinson disease. *Neurology*  
554 2014;83:1403–1409. doi:10.1212/WNL.0000000000000887.
- 555 [25] Cury RG, Galhardoni R, Fonoff ET, Dos Santos Ghilardi MG, Fonoff F, Arnaut D, Myczkowski ML,  
556 Marcolin MA, Bor-Seng-Shu E, Barbosa ER, Teixeira MJ, De Andrade DC. Effects of deep brain  
557 stimulation on pain and other nonmotor symptoms in Parkinson disease. *Neurology*  
558 2014;83:1403–1409. doi:10.1212/WNL.0000000000000887.
- 559 [26] Cury RG, Galhardoni R, Teixeira MJ, Dos Santos Ghilardi MG, Silva V, Myczkowski ML, Marcolin  
560 MA, Barbosa ER, Fonoff ET, Ciampi De Andrade D. Subthalamic deep brain stimulation

modulates conscious perception of sensory function in Parkinson's disease. *Pain* 2016;157:2758–2765. doi:10.1097/J.PAIN.0000000000000697.

[27] Cury RG, Teixeira MJ, Galhardoni R, Silva V, Iglesias R, França C, Arnaut D, Fonoff ET, Barbosa ER, Ciampi de Andrade D. Connectivity Patterns of Subthalamic Stimulation Influence Pain Outcomes in Parkinson's Disease. *Front Neurol* 2020;11. doi:10.3389/FNEUR.2020.00009.

[28] Dellapina E, Gerdelat-Mas A, Ory-Magne F, Pourcel L, Galitzky M, Calvas F, Simonetta-Moreau M, Thalamas C, Payoux P, Brefel-Courbon C. Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. *Mov Disord* 2011;26:153–157. doi:10.1002/MDS.23406.

[29] Diederich NJ, Sauvageot N, Pieri V, Hipp G, Vaillant M. The Clinical Non-Motor Connectome in Early Parkinson's Disease. *J Parkinsons Dis* 2020;10:1797. doi:10.3233/JPD-202102.

[30] Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, Capellari S, Avoni P, Baruzzi A, Liguori R. Skin nerve  $\alpha$ -synuclein deposits: a biomarker for idiopathic Parkinson disease. *Neurology* 2014;82:1362–1369. doi:10.1212/WNL.0000000000000316.

[31] Doppler K. Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson's Disease. *J Parkinsons Dis* 2021;11:937–947. doi:10.3233/JPD-202489.

[32] Doppler K, Ebert S, Üçeyler N, Trenkwalder C, Ebentheuer J, Volkmann J, Sommer C. Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. *Acta Neuropathol* 2014;128:99–109. doi:10.1007/S00401-014-1284-0.

[33] Engels G, Douw L, Kerst Y, Weinstein H, Scherder E, Vlaar A. Non-motor symptoms in Parkinson's disease: An explorative network study. *Parkinsonism Relat Disord* 2019;66:237–240.

[34] Erro Aguirre ME, Moreno MP, Zandio B. Pathophysiological bases of the non-motor symptoms in Parkinson's disease. *Rev Neurol* 2010;50.

[35] Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Santangelo G, Pellecchia MT, Barone P. The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. *Eur J Neurol* 2016;23:1673–1679. doi:10.1111/ENE.13106.

[36] Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. *Curr Opin Neurol* 2004;17:393–398. doi:10.1097/01.WCO.0000137528.23126.41.

[37] Ferreira KASL, de Andrade DC, Teixeira MJ. Development and validation of a Brazilian version of the short-form McGill pain questionnaire (SF-MPQ). *Pain Manag Nurs* 2013;14:210–219. doi:10.1016/J.PMN.2011.04.006.

[38] Filippi M, Basaia S, Sarasso E, Stojkovic T, Stankovic I, Fontana A, Tomic A, Piramide • Noemi, Stefanova E, Markovic V, Kostic VS, Agosta F. Longitudinal brain connectivity changes and clinical evolution in Parkinson's disease. *Mol Psychiatry* 2021;26:5429–5440. doi:10.1038/s41380-020-0770-0.

[39] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015;14:162–173. doi:10.1016/S1474-4422(14)70251-0.

- 603 [40] Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G,  
604 Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS.  
605 Neuropathic pain: An updated grading system for research and clinical practice. *Pain*  
606 2016;157:1599–1606.
- 607 [41] Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G,  
608 Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen TS.  
609 Neuropathic pain: an updated grading system for research and clinical practice. *Pain*  
610 2016;157:1599–1606. doi:10.1097/J.PAIN.0000000000000492.
- 611 [42] Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociceptive pain: towards  
612 an understanding of prevalent pain conditions. *Lancet* 2021;397:2098–2110.  
613 doi:10.1016/S0140-6736(21)00392-5.
- 614 [43] Fitzcharles MA, Perrot S, Häuser W. Comorbid fibromyalgia: A qualitative review of prevalence  
615 and importance. *Eur J Pain* 2018;22:1565–1576. doi:10.1002/EJP.1252.
- 616 [44] Ford B. Pain in Parkinson's disease. *Mov Disord* 2010;25 Suppl 1. doi:10.1002/MDS.22716.
- 617 [45] Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson's disease.  
618 *Mov Disord* 1996;11:421–426. doi:10.1002/MDS.870110411.
- 619 [46] Freynhagen R, Parada HA, Calderon-Ospina CA, Chen J, Rakhmawati Emril D, Fernandez-  
620 Villacorta FJ, Franco H, Ho K-Y, Lara-Solares A, Li CC-F, Mimenza Alvarado A, Nimmaanrat S,  
621 Dolma Santos M, Ciampi de Andrade D. Current understanding of the mixed pain concept: a  
622 brief narrative review. *Curr Med Res Opin* 2019;35:1011–1018.
- 623 [47] Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, Brefel-  
624 Courbon C. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. *J*  
625 *Neurol Neurosurg Psychiatry* 2007;78:1140–1142. doi:10.1136/JNNP.2007.120212.
- 626 [48] Ghosh P, Imbriani P, Caputi N, Natoli S, Schirinzi T, Di Lazzaro G, Covington L, Sparks AD,  
627 Salnikova Y, Rukavina K, Ray Chaudhuri K, Pisani A. A Dual Centre Study of Pain in Parkinson's  
628 Disease and Its Relationship with Other Non-Motor Symptoms. *J Parkinsons Dis* 2020;10:1817–  
629 1825. doi:10.3233/JPD-202088.
- 630 [49] Gibb WRG. Idiopathic Parkinson's disease and the Lewy body disorders. *Neuropathol Appl*  
631 *Neurobiol* 1986;12:223–234. doi:10.1111/J.1365-2990.1986.TB00136.X.
- 632 [50] Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. *Mov Disord*  
633 1986;1:45–49. doi:10.1002/MDS.870010106.
- 634 [51] Gowers WR. A manual of diseases of the nervous system. 1st ed. Philadelphia: Blakinston,  
635 1888.
- 636 [52] Grace AA. Physiology of the normal and dopamine-depleted basal ganglia: insights into  
637 levodopa pharmacotherapy. *Mov Disord* 2008;23 Suppl 3. doi:10.1002/MDS.22020.
- 638 [53] Granovsky Y, Schlesinger I, Fadel S, Eriq I, Sprecher E, Yarnitsky D. Asymmetric pain processing  
639 in Parkinson's disease. *Eur J Neurol* 2013;20:1375–1382. doi:10.1111/ENE.12188.
- 640 [54] Grashorn W, Schunke O, Buhmann C, Forkmann K, Diedrich S, Wesemann K, Bingel U. Influence  
641 of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients.  
642 *PLoS One* 2015;10. doi:10.1371/JOURNAL.PONE.0135287.
- 643 [55] Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: A neural networks  
644 perspective. *Brain* 2015;138:1454–1476.

- [56] Hagelberg N, Jääskeläinen SK, Martikainen IK, Mansikka H, Forssell H, Scheinin H, Hietala J, Pertovaara A. Striatal dopamine D2 receptors in modulation of pain in humans: a review. *Eur J Pharmacol* 2004;500:187–192. doi:10.1016/J.EJP.2004.07.024.
- [57] Häuser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA. Diagnostic confounders of chronic widespread pain: not always fibromyalgia. *Pain Rep* 2017;2. doi:10.1097/PR.0000000000000598.
- [58] Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson’s disease. *Neurology* 1996;47:1180–1183. doi:10.1212/WNL.47.5.1180.
- [59] Honey CR, Stoessl AJ, Tsui JKC, Schulzer M, Calne DB. Unilateral pallidotomy for reduction of parkinsonian pain. *J Neurosurg* 1999;91:198–201. doi:10.3171/JNS.1999.91.2.0198.
- [60] Kaiserova M, Kastelikova A, Grambalova Z, Otruba P, Zapletalova J, Mensikova K, Rosales R, Kanovsky P. Temperature sensation in Parkinson’s disease measured by quantitative sensory testing: a single-center, case-control study. *Int J Neurosci* 2021. doi:10.1080/00207454.2021.1991922.
- [61] Klit H, Hansen AP, Marcussen NS, Finnerup NB, Jensen TS. Early evoked pain or dysesthesia is a predictor of central poststroke pain. *Pain* 2014;155:2699–2706. doi:10.1016/J.PAIN.2014.09.037.
- [62] Koch J, Willemsen K, Dogan I, Rolke R, Schulz JB, Schiefer J, Reetz K, Maier A. Quantitative sensory testing and norepinephrine levels in REM sleep behaviour disorder - a clue to early peripheral autonomic and sensory dysfunction? *J Neurol* 2022;269:923–932. doi:10.1007/S00415-021-10675-7.
- [63] Kosek E, Clauw D, Nijs J, Baron R, Gilron I, Harris RE, Mico JA, Rice ASC, Sterling M. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. *Pain* 2021;162:2629–2634. doi:10.1097/J.PAIN.0000000000002324.
- [64] Kosek E, Clauw D, Nijs J, Baron R, Gilron I, Harris RE, Mico J-A, Rice ASC, Sterling M. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. *Pain* 2021;162:2629–2634.
- [65] Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice ASC, Rief W, Sluka AK. Do we need a third mechanistic descriptor for chronic pain states? *Pain* 2016;157:1382–1386. doi:10.1097/J.PAIN.0000000000000507.
- [66] Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice ASC, Rief W, Sluka AK. Do we need a third mechanistic descriptor for chronic pain states? *Pain* 2016;157:1382–1386. doi:10.1097/J.PAIN.0000000000000507.
- [67] Kubota GT, Soares FHC, Fonseca AS da, Rosa T dos S, Silva VA da, Gouveia GR, Faria VG, Cunha PHM da, Brunoni AR, Teixeira MJ, Andrade DC de. Pain paths among post-COVID-19 condition subjects: A prospective cross-sectional study with in-person evaluation. *European Journal of Pain* 2023. doi:10.1002/EJP.2094.
- [68] Lapa JD da S, da Cunha PHM, Teixeira MJ, Brito Medeiros VM, Fernandes AM, Silva de Moraes AD, Graven-Nielsen T, Cury RG, Ciampi de Andrade D. Burst Transspinal Magnetic Stimulation Alleviates Nociceptive Pain in Parkinson Disease-A Pilot Phase II Double-Blind, Randomized Study. *Neuromodulation* 2022. doi:10.1016/J.NEUROM.2022.10.043.

- [69] Lapa JD da S, da Cunha PHM, Teixeira MJ, Brito Medeiros VM, Fernandes AM, Silva de Moraes AD, Graven-Nielsen T, Cury RG, Ciampi de Andrade D. Burst Transspinal Magnetic Stimulation Alleviates Nociceptive Pain in Parkinson Disease—A Pilot Phase II Double-Blind, Randomized Study. *Neuromodulation: Technology at the Neural Interface* 2022. doi:10.1016/J.NEUROM.2022.10.043.
- [70] Lewy FH. *Die Lehre vom Tonus und der Bewegung: zugleich systematische Untersuchungen zur Klinik, Physiologie, Pathologie und Pathogenese der Paralysis Agitans*. Berlin: Springer, 1923 Available: [https://books.google.com.br/books/about/Die\\_Lehre\\_vom\\_Tonus\\_und\\_der\\_Bewegung.html?id=IHUcAAAAIAAJ&redir\\_esc=y](https://books.google.com.br/books/about/Die_Lehre_vom_Tonus_und_der_Bewegung.html?id=IHUcAAAAIAAJ&redir_esc=y). Accessed 18 Dec 2022.
- [71] Li J, Zhu BF, Gu ZQ, Zhang H, Mei SS, Ji SZ, Liu SY, Han C, Chen HZ, Chan P. Musculoskeletal Pain in Parkinson’s Disease. *Front Neurol* 2022;12:2494.
- [72] Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson’s disease? *Mov Disord* 2008;23:1689–1695. doi:10.1002/MDS.22111.
- [73] Listik C, Cury RG, da Silva VA, Casagrande SCB, Listik E, Link N, Galhardoni R, Barbosa ER, Teixeira MJ, Ciampi de Andrade D. Abnormal sensory thresholds of dystonic patients are not affected by deep brain stimulation. *European Journal of Pain (United Kingdom)* 2021;25:1355–1366.
- [74] Listik C, Cury RG, da Silva VA, Casagrande SCB, Listik E, Link N, Galhardoni R, Barbosa ER, Teixeira MJ, Ciampi de Andrade D. Abnormal sensory thresholds of dystonic patients are not affected by deep brain stimulation. *Eur J Pain* 2021;25:1355–1366. doi:10.1002/EJP.1757.
- [75] Listik C, Listik E, Cury RG, Barbosa ER, Teixeira MJ, de Andrade DC. Deep brain stimulation treatment in dystonia: a bibliometric analysis. *Arq Neuropsiquiatr* 2020;78:586–592. doi:10.1590/0004-282X20200016.
- [76] Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. *Pain* 2008;137:473–477. doi:10.1016/J.PAIN.2008.04.025.
- [77] Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. *Pain* 2008;137:473–477.
- [78] Lopes LCG, Galhardoni R, Silva V, Jorge FMH, Yeng LT, Callegaro D, Chadi G, Teixeira MJ, Ciampi de Andrade D. Beyond weakness: Characterization of pain, sensory profile and conditioned pain modulation in patients with motor neuron disease: A controlled study. *Eur J Pain* 2018;22:72–83.
- [79] Lozano AM, Dostrovsky J, Chen R, Ashby P. Deep brain stimulation for Parkinson’s disease: Disrupting the disruption. *Lancet Neurology* 2002;1:225–231. doi:10.1016/S1474-4422(02)00101-1.
- [80] Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C. How to diagnose parkinsonian central pain? *Parkinsonism Relat Disord* 2019;64:50–53. doi:10.1016/J.PARKRELDIS.2019.04.025.
- [81] Marques A, Brefel-Courbon C. Chronic pain in Parkinson’s disease: Clinical and pathophysiological aspects. *Rev Neurol (Paris)* 2021;177:394–399. doi:10.1016/J.NEUROL.2020.06.015.

- 728 [82] Marques A, Chassin O, Morand D, Pereira B, Debilly B, Derost P, Ulla M, Lemaire JJ, Durif F.  
729 Central pain modulation after subthalamic nucleus stimulation: A crossover randomized trial.  
730 Neurology 2013;81:633–640. doi:10.1212/WNL.0B013E3182A08D00.
- 731 [83] Marras C, Chaudhuri KR. Nonmotor features of Parkinson’s disease subtypes. Movement  
732 Disorders 2016;31:1095–1102. doi:10.1002/MDS.26510.
- 733 [84] Marras C, Chaudhuri KR, Titova N, Mestre TA. Therapy of Parkinson’s Disease Subtypes.  
734 Neurotherapeutics 2020;17:1366–1377. doi:10.1007/S13311-020-00894-7.
- 735 [85] Martikainen IK, Hagelberg N, Mansikka H, Hietala J, Någren K, Scheinin H, Pertovaara A.  
736 Association of striatal dopamine D2/D3 receptor binding potential with pain but not tactile  
737 sensitivity or placebo analgesia. Neurosci Lett 2005;376:149–153.  
738 doi:10.1016/J.NEULET.2004.11.045.
- 739 [86] Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor  
740 symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord  
741 2011;26:399–406. doi:10.1002/MDS.23462.
- 742 [87] Mathieu S, Couderc M, Pereira B, Dubost JJ, Malochet-Guinamand S, Tournadre A, Soubrier M,  
743 Moisset X. Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases. J Clin Med  
744 2020;9:1–13. doi:10.3390/JCM9061890.
- 745 [88] Michely J, Volz LJ, Barbe MT, Hoffstaedter F, Viswanathan S, Timmermann L, Eickhoff SB, Fink  
746 GR, Grefkes C. Dopaminergic modulation of motor network dynamics in Parkinson’s disease.  
747 Brain 2015;138:664–678. doi:10.1093/BRAIN/AWU381.
- 748 [89] Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P. Migraine headaches and pain  
749 with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain  
750 2013;154:2691–2699. doi:10.1016/J.PAIN.2013.07.050.
- 751 [90] Mylius V. Exercise in Parkinson’s disease: Experimental-induced pain sensitivity is reduced  
752 already after short term training. European Journal of Pain (United Kingdom) 2019;23:1585.
- 753 [91] Mylius V. Exercise in Parkinson’s disease: Experimental-induced pain sensitivity is reduced  
754 already after short term training. Eur J Pain 2019;23:1585. doi:10.1002/EJP.1468.
- 755 [92] Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, Möller JC. Pain sensitivity and  
756 clinical progression in Parkinson’s disease. Mov Disord 2011;26:2220–2225.  
757 doi:10.1002/MDS.23825.
- 758 [93] Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, Beer S, Kesselring J,  
759 Stamelou M, Oertel WH, Möller JC, Lefaucheur JP. Pain in Parkinson’s Disease: Current  
760 Concepts and a New Diagnostic Algorithm. Mov Disord Clin Pract 2015;2:357–364.  
761 doi:10.1002/MDC3.12217.
- 762 [94] Mylius V, Engau I, Teepker M, Stiasny-Kolster K, Schepelmann K, Oertel WH, Lautenbacher S,  
763 Möller JC. Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol  
764 Neurosurg Psychiatry 2009;80:24–28. doi:10.1136/JNNP.2008.145995.
- 765 [95] Mylius V, Möller JC, Bohlhalter S, Ciampi de Andrade D, Perez Lloret S. Diagnosis and  
766 Management of Pain in Parkinson’s Disease: A New Approach. Drugs Aging 2021;38:559–577.  
767 doi:10.1007/S40266-021-00867-1.
- 768 [96] Mylius V, Moller JC, Bohlhalter S, Ciampi de Andrade D, Perez Lloret S. Diagnosis and  
769 Management of Pain in Parkinson’s Disease: A New Approach. Drugs Aging 2021;38:559–577.

- 770 [97] Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, Moreira LI, Listik C,  
771 Fernandes AM, de Lacerda Veiga D, Barbour J, Hollenstein N, Oechsner M, Walch J, Brugger F,  
772 Hägele-Link S, Beer S, Rizos A, Chaudhuri KR, Bouhassira D, Lefaucheur JP, Timmermann L,  
773 Gonzenbach R, Kägi G, Möller JC, Ciampi de Andrade D. The Parkinson disease pain  
774 classification system: results from an international mechanism-based classification approach.  
775 *Pain* 2021;162:1201–1210. doi:10.1097/J.PAIN.0000000000002107.
- 776 [98] Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, Moreira LI, Listik C,  
777 Fernandes AM, de Lacerda Veiga D, Barbour J, Hollenstein N, Oechsner M, Walch J, Brugger F,  
778 Hagele-Link S, Beer S, Rizos A, Chaudhuri KR, Bouhassira D, Lefaucheur J-P, Timmermann L,  
779 Gonzenbach R, Kagi G, Moller JC, Ciampi de Andrade D. The Parkinson disease pain  
780 classification system: results from an international mechanism-based classification approach.  
781 *Pain* 2021;162:1201–1210.
- 782 [99] Nandhagopal R, Troiano AR, Mak E, Schulzer M, Bushnell MC, Stoessl AJ. Response to heat pain  
783 stimulation in idiopathic Parkinson’s disease. *Pain Med* 2010;11:834–840. doi:10.1111/J.1526-  
784 4637.2010.00866.X.
- 785 [100] Nicholas M, Vlaeyen JWS, Rief W, Barke A, Aziz Q, Benoliel R, Cohen M, Evers S, Giamberardino  
786 MA, Goebel A, Korwisi B, Perrot S, Svensson P, Wang SJ, Treede RD. The IASP classification of  
787 chronic pain for ICD-11: chronic primary pain. *Pain* 2019;160:28–37.  
788 doi:10.1097/J.PAIN.0000000000001390.
- 789 [101] Nicholas M, Vlaeyen JWS, Rief W, Barke A, Aziz Q, Benoliel R, Cohen M, Evers S, Giamberardino  
790 MA, Goebel A, Korwisi B, Perrot S, Svensson P, Wang SJ, Treede RD. The IASP classification of  
791 chronic pain for ICD-11: Chronic primary pain. *Pain* 2019;160:28–37.
- 792 [102] Nijs J, Ickmans K, Polli A, Huysmans E, Carlos J, Nijs J, George SZ, Clauw DJ, Fernández-de-las-  
793 Peñas C, Kosek E, Ickmans K, Fernández-Carnero J, Polli A, Kapreli E, Huysmans E, Cuesta-Vargas  
794 AI, Mani R, Lundberg M, Leysen L, Rice D, Sterling M, Curatolo M. Central sensitisation in  
795 chronic pain conditions: latest discoveries and their potential for precision medicine. *Review*  
796 *Lancet Rheumatol* 2021;3:383–92. doi:10.1016/S2665-9913(21)00032-1.
- 797 [103] Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. *Drugs*  
798 *Aging* 2013;30:587–592. doi:10.1007/S40266-013-0090-Z.
- 799 [104] Nolano M, Provitera V, Stancanelli A, Saltalamacchia AM, Caporaso G, Lullo F, Borreca I,  
800 Piscosquito G, Mozzillo S, Esposito M, Manganelli F, Lanzillo B, Santoro L. Small fiber pathology  
801 parallels disease progression in Parkinson disease: a longitudinal study. *Acta Neuropathol*  
802 2018;136:501–503. doi:10.1007/S00401-018-1876-1.
- 803 [105] Nugraha B, Gutenbrunner C, Barke A, Karst M, Schiller J, Schäfer P, Falter S, Korwisi B, Rief W,  
804 Treede RD. The IASP classification of chronic pain for ICD-11: functioning properties of chronic  
805 pain. *Pain* 2019;160:88–94. doi:10.1097/J.PAIN.0000000000001433.
- 806 [106] Onu M, Badea L, Roceanu A, Tivarus M, Bajenaru O. Increased connectivity between  
807 sensorimotor and attentional areas in Parkinson’s disease. *Neuroradiology* 2015;57:957–968.
- 808 [107] Parkinson J. AN ESSAY ON THE SHAKING PALSY. *Arch Neurol* 1969;20:441–445.  
809 doi:10.1001/ARCHNEUR.1969.00480100117017.

- 810 [108] Pasquini J, Ceravolo R, Qamhawi Z, Lee JY, Deuschl G, Brooks DJ, Bonuccelli U, Pavese N.  
811 Progression of tremor in early stages of Parkinson's disease: a clinical and neuroimaging study.  
812 *Brain* 2018;141:811–821. doi:10.1093/BRAIN/AWX376.
- 813 [109] Perez-Lloret S, Ciampi de Andrade D, Lyons KE, Rodríguez-Blázquez C, Chaudhuri KR, Deuschl G,  
814 Cruccu G, Sampaio C, Goetz CG, Schrag A, Martinez-Martin P, Stebbins G, Cubo E, Hall D, Luo S,  
815 Marinus J, Marsh L, Skorvanek M. Rating Scales for Pain in Parkinson's Disease: Critique and  
816 Recommendations. *Mov Disord Clin Pract* 2016;3:527–537. doi:10.1002/MDC3.12384.
- 817 [110] Quinn NP, Lang AE, Koller WC, Marsden CD. Painful Parkinson's disease. *Lancet* 1986;1:1366–  
818 1369. doi:10.1016/S0140-6736(86)91674-0.
- 819 [111] Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M,  
820 Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised  
821 International Association for the Study of Pain definition of pain: concepts, challenges, and  
822 compromises. *Pain* 2020;161:1976–1982. doi:10.1097/J.PAIN.0000000000001939.
- 823 [112] Riffbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML, Bliddal H, Kristensen LE,  
824 Danneskiold-Samsøe B, Amris K. Pain and pain mechanisms in patients with inflammatory  
825 arthritis: A Danish nationwide cross-sectional DANBIO registry survey. *PLoS One* 2017;12.
- 826 [113] Sauerbier A, Qamar MA, Rajah T, Chaudhuri KR. New concepts in the pathogenesis and  
827 presentation of Parkinson's disease. *Clin Med (Lond)* 2016;16:365–370.  
828 doi:10.7861/CLINMEDICINE.16-4-365.
- 829 [114] Sauerbier A, Rosa-Grilo M, Qamar MA, Chaudhuri KR. Nonmotor Subtyping in Parkinson's  
830 Disease. *Int Rev Neurobiol* 2017;133:447–478. doi:10.1016/BS.IRN.2017.05.011.
- 831 [115] Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D,  
832 Sampaio C, Chahine L, Hametner EM, Heim B, Lim SY, Poewe W, Djamshidian-Tehrani A. Update  
833 on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine  
834 review. *Mov Disord* 2019;34:180–198. doi:10.1002/MDS.27602.
- 835 [116] Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM,  
836 Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based  
837 Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.  
838 *Mov Disord* 2011;26 Suppl 3. doi:10.1002/MDS.23884.
- 839 [117] Slaoui T, Mas-Gerdelat A, Ory-Magne F, Rascol O, Brefel-Courbon C. [Levodopa modifies pain  
840 thresholds in Parkinson's disease patients]. *Rev Neurol (Paris)* 2007;163:66–71.  
841 doi:10.1016/S0035-3787(07)90356-2.
- 842 [118] Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. *Neurology*  
843 1976;26:423–429. doi:10.1212/WNL.26.5.423.
- 844 [119] Souques MA. Des douleurs dans la paralysie agitante. *Rev Neurol (Paris)* 1921;37:629–633.
- 845 [120] Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH,  
846 Chaudhuri KR, Koch R, Reichmann H, Ebersbach G. Nonmotor fluctuations in Parkinson disease:  
847 severity and correlation with motor complications. *Neurology* 2013;80:800–809.  
848 doi:10.1212/WNL.0B013E318285C0ED.
- 849 [121] Strobel A V., Tankisi H, Finnerup NB, Fuglsang-Frederiksen A, Jennum P, Svendsen KB, Kirov FI,  
850 Otto M. Somatosensory function is impaired in patients with idiopathic REM sleep behaviour  
851 disorder. *Sleep Med* 2018;42:83–89. doi:10.1016/J.SLEEP.2017.09.035.

- 852 [122] Thobois S, Vingerhoets F, Fraix V, Xie-Brustolin J, Mollion H, Costes N, Mertens P, Benabid AL,  
853 Pollak P, Broussolle E. Role of dopaminergic treatment in dopamine receptor down-regulation  
854 in advanced Parkinson disease: a positron emission tomographic study. *Arch Neurol*  
855 2004;61:1705–1709. doi:10.1001/ARCHNEUR.61.11.1705.
- 856 [123] Treede RD. Gain control mechanisms in the nociceptive system. *Pain* 2016;157:1199–1204.
- 857 [124] Treede R-D, Hoheisel U, Wang D, Magerl W. Biennial Review of Pain Central sensitization:  
858 clinical utility of a physiological concept for the International Statistical Classification of  
859 Diseases and Related Health Problems and for nociplastic pain. 2022.  
860 doi:10.1097/j.pain.0000000000002740.
- 861 [125] Treede RD, Hoheisel U, Wang D, Magerl W. Central sensitization: clinical utility of a  
862 physiological concept for the International Statistical Classification of Diseases and Related  
863 Health Problems and for nociplastic pain. *Pain* 2022;163:S99–S107.  
864 doi:10.1097/J.PAIN.0000000000002740.
- 865 [126] Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R,  
866 Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and  
867 research purposes. *Neurology* 2008;70:1630–1635.  
868 doi:10.1212/01.WNL.0000282763.29778.59.
- 869 [127] Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R,  
870 Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and  
871 research purposes. *Neurology* 2008;70:1630–1635.  
872 doi:10.1212/01.WNL.0000282763.29778.59.
- 873 [128] Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First  
874 MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand’Homme P, Nicholas M, Perrot S,  
875 Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a symptom or a  
876 disease: the IASP Classification of Chronic Pain for the International Classification of Diseases  
877 (ICD-11). *Pain* 2019;160:19–27. doi:10.1097/J.PAIN.0000000000001384.
- 878 [129] Truini A, Prosperini L, Calistri V, Fiorelli M, Pozzilli C, Millefiorini E, Frontoni M, Cortese A,  
879 Caramia F, Cruccu G. A dual concurrent mechanism explains trigeminal neuralgia in patients  
880 with multiple sclerosis. *Neurology* 2016;86:2094–2099. doi:10.1212/WNL.0000000000002720.
- 881 [130] Valerio F, Apostolos-Pereira SL, Sato DK, Callegaro D, Lucato LT, Barboza VR, Silva VA,  
882 Galhardoni R, Rodrigues AL de L, Jacobsen Teixeira M, Ciampi de Andrade D. Characterization  
883 of pain syndromes in patients with neuromyelitis optica. *European Journal of Pain (United*  
884 *Kingdom)* 2020;24:1548–1568.
- 885 [131] Vela L, Cano-de-la-Cuerda R, Fil A, Muñoz-Hellín E, Ortiz-Gutiérrez R, Macías-Macías Y,  
886 Fernández-de-las-Peñas C. Thermal and mechanical pain thresholds in patients with fluctuating  
887 Parkinson’s disease. *Parkinsonism Relat Disord* 2012;18:953–957.  
888 doi:10.1016/J.PARKRELDIS.2012.04.031.
- 889 [132] Viisanen H, Ansah OB, Pertovaara A. The role of the dopamine D2 receptor in descending  
890 control of pain induced by motor cortex stimulation in the neuropathic rat. *Brain Res Bull*  
891 2012;89:133–143. doi:10.1016/J.BRAINRESBULL.2012.08.002.

- [133] Wallace VCJ, Chaudhuri KR. Unexplained lower limb pain in Parkinson's disease: a phenotypic variant of "painful Parkinson's disease." *Parkinsonism Relat Disord* 2014;20:122–124. doi:10.1016/J.PARKRELDIS.2013.09.016.
- [134] Wang DD, de Hemptinne C, Miocinovic S, Ostrem JL, Galifianakis NB, Luciano MS, Starr PA. Pallidal Deep-Brain Stimulation Disrupts Pallidal Beta Oscillations and Coherence with Primary Motor Cortex in Parkinson's Disease. *J Neurosci* 2018;38:4556–4568. doi:10.1523/JNEUROSCI.0431-18.2018.
- [135] Wasner G, Deuschl G. Pains in Parkinson disease--many syndromes under one umbrella. *Nat Rev Neurol* 2012;8:284–294. doi:10.1038/NRNEUROL.2012.54.
- [136] Weiss JL, Chase TN. Levodopa in Parkinsonism. *Drugs* 1971 2:4 2012;2:257–261. doi:10.2165/00003495-197102040-00001.
- [137] Williams ACDC, Craig KD. Updating the definition of pain. *Pain* 2016;157:2420–2423. doi:10.1097/J.PAIN.0000000000000613.
- [138] Wilson SAK. *Neurology*. New York: Hafner Publishing, 1940.
- [139] Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Ali Chérif A. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. *Neurology* 2002;59:408–413. doi:10.1212/WNL.59.3.408.
- [140] Witjas T, Kaphan E, Régis J, Jouve E, Chérif AA, Péragut JC, Azulay JP. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. *Mov Disord* 2007;22:1729–1734. doi:10.1002/MDS.21602.
- [141] Wolz M, Hauschild J, Fauser M, Klingelhöfer L, Reichmann H, Storch A. Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. *Parkinsonism Relat Disord* 2012;18:994–997. doi:10.1016/J.PARKRELDIS.2012.05.011.
- [142] Yoritaka A, Shimo Y, Takanashi M, Fukae J, Hatano T, Nakahara T, Miyamoto N, Urabe T, Mori H, Hattori N. Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks. *Parkinsonism Relat Disord* 2013;19:725–731. doi:10.1016/J.PARKRELDIS.2013.04.001.
- [143] Zambito-Marsala S, Erro R, Bacchin R, Fornasier A, Fabris F, Lo Cascio C, Ferracci F, Morgante F, Tinazzi M. Abnormal nociceptive processing occurs centrally and not peripherally in pain-free Parkinson disease patients: A study with laser-evoked potentials. *Parkinsonism Relat Disord* 2017;34:43–48. doi:10.1016/J.PARKRELDIS.2016.10.019.
- [144] Zibetti M, Torre E, Cinquepalmi A, Rosso M, Ducati A, Bergamasco B, Lanotte M, Lopiano L. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. *Eur Neurol* 2007;58:218–223. doi:10.1159/000107943.
- [145] Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR. The range and nature of non-motor symptoms in drug-naïve Parkinson's disease patients: a state-of-the-art systematic review. *NPJ Parkinsons Dis* 2015;1. doi:10.1038/NPJPARKD.2015.13.

## Figures titles and legends

### **Fig 1. Summary of the main current classification and scoring systems for pain in patients with Parkinson's disease.**

PD (Parkinson's disease) related pain includes new pain and previous pain aggravated by PD. Since pain may precede motor symptoms by several years, determining if a pain is emerging *de novo* as motor symptoms appear, or if it is a previous pain that was aggravated by PD can be challenging clinically. So, a pragmatic approach is to merge these two instances under PD-related pain. Such strategy has been validated [98](Mylius 2021) and showed to provide classification of pain based on mechanistic descriptors. To be considered PD-related pain, chronic pain had to fulfil at least one of the following prerequisites: i. Pain started or became more severe after other PD symptoms started, ii. Pain is aggravated when rigidity, tremors or slowness of movements are more intense, iii. Pain is associated with excessive, abnormal movements (choreiform dyskinesia), iv. Pain is somehow improved when PD medications are taken (based on Quinn 1986 [95], Wasner & Deuschl 2012 [114], Mylius 2015 [83])

\* Data refer to the prevalence of chronic pain in PD in general (up to 80%) [8,13], and to the prevalence of PD-related pain within the chronic pain sample [97].

\*\* footnotes on subtypes: in the ICD-11 framework - 1. MG30.32 – chronic secondary musculoskeletal pain due to disease of the nervous system, or 2. MG30.50: chronic central neuropathic pain, or 3. MG30.Z “chronic pain, unspecified”. In the mechanistic descriptor framework, 1. is nociceptive, 2. is neuropathic, and 3. “other”, as it concerns those who did not fulfill nociceptive or neuropathic criteria according to (Mylius et al., 2021 [96,98]. In the original publication it was termed “nociplastic” as a synonym for non-nociceptive/non-neuropathic, as the published grading system [64] is not suitable to identify these cases.